2024年11月12日 · We are committed to the development of novel and differentiated cancer therapies intended to overcome known drug resistance mechanisms in combination with …

We are a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Our pipeline includes clinical-stage drug candidates each with its own unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid …

Find the latest MEI Pharma, Inc. (MEIP) stock quote, history, news and other vital information to help you with your stock trading and investing.

2023年2月23日 · ME-344, a novel tumor selective mitochondrial inhibitor targeting the OXPHOS pathway, to be evaluated in combination with bevacizumab (AVASTIN®) in patients with …

2025年2月12日 · The mission at MEI Pharma is to develop novel and differentiated cancer therapies intended to improve patient benefit. Our approach to oncology drug development is …

MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to …

2023年2月23日 · Morgan Lewis is representing MEI Pharma Inc. in a definitive merger agreement with Infinity Pharmaceuticals Inc. for an all-stock transaction, forming a new company to …

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.

MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its programs include Voruciclib and ME-344. The company was …